2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid

• ChemBase编号: 73170
• 分子式: C13H14Cl2O3
• 平均质量: 289.15446
• 单一同位素质量: 288.03199967
• SMILES: c1c(ccc(c1)OC(C(=O)O)(C)C)C1C(C1)(Cl)Cl
• Canonical SMILES: OC(=O)C(Oc1ccc(cc1)C1CC1(Cl)Cl)(C)C
• InChI: InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
• InChIKey: KPSRODZRAIWAKH-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid
• IUPAC传统名: ciprofibrate; 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid
• 别名: Ciprofibrate; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic Acid; (±)-Ciprofibrate; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropionic Acid; Ciprol; Lipanor; Modalim; Win 35833; 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; Ciprofibrate

登记号

• CAS号: 52214-84-3
• EC号: 257-744-6
• MDL号: MFCD00467135
• PubChem SID: 162038090; 24278288
• PubChem CID: 2763

理论计算性质

• Acid pKa: 3.6873658
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): 1.8113741
• LogD (pH = 7.4): 0.3118669
• Log P: 3.6223862
• 摩尔折射率: 70.5022 cm^3
• 极化性: 27.351288 Å^3
• 极化表面积: 46.53 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

分子性质

安全信息

• 保存条件: -20°C
• RTECS编号: UF0880000
• 欧盟危险性物质标志: 有毒(Toxic) (T)
• 德国WGK号: 3
• 危险公开号: 45
• 安全公开号: 53-22-36/37/39-45
• GHS危险品标识: GHS08
• GHS警示词: Danger
• GHS危险声明: H350
• GHS警示性声明: P201-P308 + P313
• 个人保护装置: Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges
• 保存温度: 2-8°C

药理学性质

• 相关基因信息: human ... PPARA(5465)
• 生物活性机理: Agonist of the PPARalpha receptor in muscle, liver, and other tissues

产品相关信息

• 纯度: 95+%; 97%
• 成盐信息: Free Base
• 应用领域: Effective in type Iia, Iib, III and IV hyperlipoproteinaemias and increases high-density lipoprotein; Hypolipidaemic agent

详细说明

Selleck Chemicals - S2665

Research Area: Cardiovascular Disease
Biological Activity:
Ciprofibrate is a peroxisome proliferator-activated receptor agonist. [1] It was reported that ciprofibrate decreased the levels of plasma triglycerides and total cholesterol as well as low-density lipoprotein cholesterol. Meanwhile, ciprofibrate elevated plasma levels of high-density lipoprotein cholesterol. The maximum concentration time of ciprofibrate is between one hour and 2.5 hours while the long half life (80 -100 h) permits daily dosing of the drug. In addition, the maximum plasma concentration is between 66 and 88 μg/mL after chronic administration of 100 mg/day of ciprofibrate. Ciprofibrate belongs to the second generation of fibric acid derivatives which used to treat patients with dyslipidaemias of various types. [2]

Sigma Aldrich - C0330

Biochem/physiol Actions
Peroxisome proliferator-activated receptor α (PPARα) agonist
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. C0330.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Toronto Research Chemicals - C482475

Ciprofibrate is a hypolipemic agent, related structurally to Clofibrate (C586910). Ciprofibrate is used as an antilipemic.

参考文献

• Steed MM et al. Antioxid Redox Signal. 2011 Oct 1;15(7):1927-43.
• Davison, C., et al.: Drug. Metab. Dispos., 3, 520 (1975)
• Arnold, A., et al.: J. Pharm. Sci., et al.: 68, 1557 (1975)
• Tuchman-Duplessis, H., et al.: Toxicology, 12, 1 (1975)
• Fr. Pat., 1974, Sterling Drug, 2 197 586; CA, 82, 43059m, (synth, pharmacol)
• Arnold, A. et al., J. Pharm. Sci., 1979, 68, 1557, (props)
• Beyer, K.H. et al., Arch. Pharm. (Weinheim, Ger.), 1982, 315, 1049, (metab)
• Gibson, G. et al., Peroxisomes: Biology and Importance in Toxicology and Medicine, Taylor and Francis, London, 1993, (rev)
• Chapman, M.J. et al., Atherosclerosis (Amsterdam), 1996, 124; S83, (pharmacol, use)
• Masnatta, L.D. et al., J. Chromatogr., B: Biomed. Appl., 1996, 687, 437, (hplc)
• Martindale, The Extra Pharmacopoeia, 31st edn., Pharmaceutical Press, 1996, 1304
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, CMS210